Trial Profile
An Ascending-dose, Randomized, Placebo-controlled, Parallel, Double-blind, Single-dose, First-in-Human Study to Evaluate the Safety and Pharmacokinetics of RECCE327 in Healthy Male Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs RECCE 327 (Primary) ; Cetirizine
- Indications Bacterial infections; Burn infections; Clostridium infections; COVID 2019 infections; Escherichia coli infections; Sepsis; Streptococcal infections
- Focus Adverse reactions; First in man
- Sponsors Recce Pharmaceuticals
- 13 Mar 2024 According to a Recce Pharmaceuticals media release, the company will present data from this study at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
- 20 Jul 2023 According to a Recce Pharmaceuticals media release, the company will provide interim proof-of-efficacy data in pre-sepsis patients in H2 2023.
- 20 Jul 2023 Positive results (n=80) of this study presented in a Recce Pharmaceuticals media release.